Pfizer failed to report hundreds of serious adverse drug reactions (ADRs) in the required timeframes according to Japan’s Ministry of Health, Labor and Welfare (MHLW) which has issued the US firm with a business improvement order.
Sanofi wants to expand its inhalable drug production site in Cheshire, UK to increase capacity for both its own brand drug production operations and its contract manufacturing business.
GLP-1 drugs and oral formulations will not diminish demand for insulin patch-pumps says CeQur, which has raised $100m (€89m) to support production of its PaQ delivery device.
Sandoz has launched Zarxio, the first biosimilar in the US, despite a last ditch effort to block the copycat version of Neupogen by Amgen.
Pfizer has confirmed it is in discussion with labour unions in Korea as part of an evaluation of its business in the country.
Amgen has retracted a study showing how grizzly bears could hold the key to understanding diabetes after one of the authors was found to have manipulated data.